Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study
Primary Purpose
Hypertension
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Pine Bark Extract (Flavangenol®)
Sponsored by

About this trial
This is an interventional prevention trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Systolic blood pressure between 125 and 159 mmHg and diastolic blood pressure (DBP) < 100 mmHg
- Body mass index (BMI) 25.0-34.9
- Triglycerides (TG) < 450 mg/dL
- Low Density Lipoprotein (LDL) < 200 mg/dL
- Fasting blood glucose (FBG) < 126 mg/dL
Exclusion Criteria:
- DBP > 95 mmHg
- LDL > 170 mg/dL
- TG > 300 mg/dL
- FBG > 110 mg/dL
Sites / Locations
- Stanford University School of Medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
Placebo
Pine Bark Extract
Arm Description
Placebo delivered as four tablets matching the active product once daily orally.
Flavangenol 200 mg Flavangenol is a brand of Pine Bark Extract manufactured by Toyo Shinyaku of Saga, Japan. Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day.
Outcomes
Primary Outcome Measures
Combined Change in Systolic and Diastolic Blood Pressures From Baseline to Week 12.
Mean at Week 12 observation minus mean at Baseline observation.
Secondary Outcome Measures
Total Cholesterol
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
LDL
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
HDL
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Triglycerides
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
LDL Particle Size
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
HDL Particle Size
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Lipoprotein A
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up). Calculated as (Pinebark_Followup - Pinebark_Baseline) - (Placebo_Follow-up - Placebo_Baseline)
C-reactive Protein
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Body Mass Index
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Weight
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Fasting Blood Glucose
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Fasting Insulin
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Hemoglobin A1c
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
ALT/SGPT
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
AST/SGOT
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Full Information
NCT ID
NCT00425945
First Posted
January 23, 2007
Last Updated
February 19, 2014
Sponsor
Stanford University
Collaborators
Funded by Toyo Shinyaku Co Ltd
1. Study Identification
Unique Protocol Identification Number
NCT00425945
Brief Title
Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study
Official Title
Cardiovascular Effects of Pine Bark Extract
Study Type
Interventional
2. Study Status
Record Verification Date
February 2014
Overall Recruitment Status
Completed
Study Start Date
October 2006 (undefined)
Primary Completion Date
August 2008 (Actual)
Study Completion Date
August 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Stanford University
Collaborators
Funded by Toyo Shinyaku Co Ltd
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to investigate the efficacy of Flavangenol® (Toyo Shinyaku, Japan), a pine bark extract, in lowering blood pressure and improving glycemic control and plasma lipoprotein profile.
Detailed Description
Cardiovascular disease is the number one cause of death in the Unites States. Our study tests the efficacy of pine bark extract in improving a number of cardiovascular disease risk factors. We are conducting a randomized, placebo-controlled, double-blind, parallel trial that will investigate the efficacy and safety of Flavangenol® (Toyo Shinyaku, Japan), a pine bark extract, among 130 study participants. These participants will be individuals at mildly or moderately elevated risk of cardiovascular disease (CVD) because of having prehypertension, excess body weight, and insulin insensitivity. We aim to determine (in order of priority):
The efficacy of Flavangenol in lowering blood pressure.
The efficacy of Flavangenol in improving glycemic control and plasma lipoprotein profile.
Changes in body weight, antioxidative capacity, anti-inflammatory markers, blood coagulation factors, and liver function tests in response to Flavangenol.
The safety of Flavangenol, as confirmation of past studies.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
130 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo delivered as four tablets matching the active product once daily orally.
Arm Title
Pine Bark Extract
Arm Type
Active Comparator
Arm Description
Flavangenol 200 mg Flavangenol is a brand of Pine Bark Extract manufactured by Toyo Shinyaku of Saga, Japan. Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day.
Intervention Type
Drug
Intervention Name(s)
Pine Bark Extract (Flavangenol®)
Other Intervention Name(s)
Pycnogenol (differing formulation)
Intervention Description
Flavangenol 200 mg per day. Flavangenol is a brand of pine bark extract manufactured by Toyo Shinyaku of Saga, Japan.
Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day orally for 12 weeks.
Primary Outcome Measure Information:
Title
Combined Change in Systolic and Diastolic Blood Pressures From Baseline to Week 12.
Description
Mean at Week 12 observation minus mean at Baseline observation.
Time Frame
three months
Secondary Outcome Measure Information:
Title
Total Cholesterol
Description
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Time Frame
3 months
Title
LDL
Description
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Time Frame
3 months
Title
HDL
Description
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Time Frame
3 months
Title
Triglycerides
Description
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Time Frame
three months
Title
LDL Particle Size
Description
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Time Frame
3 months
Title
HDL Particle Size
Description
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Time Frame
3 months
Title
Lipoprotein A
Description
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up). Calculated as (Pinebark_Followup - Pinebark_Baseline) - (Placebo_Follow-up - Placebo_Baseline)
Time Frame
three months
Title
C-reactive Protein
Description
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Time Frame
three months
Title
Body Mass Index
Description
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Time Frame
three months
Title
Weight
Description
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Time Frame
3 months
Title
Fasting Blood Glucose
Description
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Time Frame
three months
Title
Fasting Insulin
Description
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Time Frame
three months
Title
Hemoglobin A1c
Description
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Time Frame
three months
Title
ALT/SGPT
Description
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Time Frame
three months
Title
AST/SGOT
Description
Net change in secondary outcomes from Baseline to 12 Weeks (Follow-up).
Time Frame
three months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Systolic blood pressure between 125 and 159 mmHg and diastolic blood pressure (DBP) < 100 mmHg
Body mass index (BMI) 25.0-34.9
Triglycerides (TG) < 450 mg/dL
Low Density Lipoprotein (LDL) < 200 mg/dL
Fasting blood glucose (FBG) < 126 mg/dL
Exclusion Criteria:
DBP > 95 mmHg
LDL > 170 mg/dL
TG > 300 mg/dL
FBG > 110 mg/dL
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Randall S. Stafford MD, PhD
Organizational Affiliation
Stanford University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Stanford University School of Medicine
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
20876405
Citation
Drieling RL, Gardner CD, Ma J, Ahn DK, Stafford RS. No beneficial effects of pine bark extract on cardiovascular disease risk factors. Arch Intern Med. 2010 Sep 27;170(17):1541-7. doi: 10.1001/archinternmed.2010.310.
Results Reference
result
Learn more about this trial
Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study
We'll reach out to this number within 24 hrs